[go: up one dir, main page]

LT3703658T - Lipidų nanodalelės, skirtos modifikuotos rnr, koduojančios vegf-a polipeptidą, pristatymui - Google Patents

Lipidų nanodalelės, skirtos modifikuotos rnr, koduojančios vegf-a polipeptidą, pristatymui

Info

Publication number
LT3703658T
LT3703658T LTEPPCT/US2018/058541T LTUS2018058541T LT3703658T LT 3703658 T LT3703658 T LT 3703658T LT US2018058541 T LTUS2018058541 T LT US2018058541T LT 3703658 T LT3703658 T LT 3703658T
Authority
LT
Lithuania
Prior art keywords
vegf
polypeptide
lipid nanoparticles
modified rna
rna encoding
Prior art date
Application number
LTEPPCT/US2018/058541T
Other languages
English (en)
Inventor
Kenny Hansson
Kerry BENENATO
Maria WÅGBERG
Annika PÅLSSON
Regina FRITSCHE-DANIELSON
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LT3703658T publication Critical patent/LT3703658T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEPPCT/US2018/058541T 2017-10-31 2018-10-31 Lipidų nanodalelės, skirtos modifikuotos rnr, koduojančios vegf-a polipeptidą, pristatymui LT3703658T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579671P 2017-10-31 2017-10-31
PCT/US2018/058541 WO2019089818A1 (en) 2017-10-31 2018-10-31 Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide

Publications (1)

Publication Number Publication Date
LT3703658T true LT3703658T (lt) 2022-07-25

Family

ID=64557129

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/058541T LT3703658T (lt) 2017-10-31 2018-10-31 Lipidų nanodalelės, skirtos modifikuotos rnr, koduojančios vegf-a polipeptidą, pristatymui

Country Status (24)

Country Link
US (1) US11696892B2 (lt)
EP (1) EP3703658B1 (lt)
JP (2) JP7308000B2 (lt)
KR (1) KR20200081420A (lt)
CN (1) CN111356444A (lt)
AU (1) AU2018358049A1 (lt)
BR (1) BR112020008404A2 (lt)
CA (1) CA3080592A1 (lt)
CY (1) CY1125373T1 (lt)
DK (1) DK3703658T3 (lt)
EA (1) EA202090919A1 (lt)
ES (1) ES2922462T3 (lt)
HR (1) HRP20220843T1 (lt)
HU (1) HUE059049T2 (lt)
IL (1) IL274230B2 (lt)
LT (1) LT3703658T (lt)
MA (1) MA50522B1 (lt)
PL (1) PL3703658T3 (lt)
PT (1) PT3703658T (lt)
RS (1) RS63389B1 (lt)
SG (1) SG11202003941XA (lt)
SI (1) SI3703658T1 (lt)
SM (1) SMT202200296T1 (lt)
WO (1) WO2019089818A1 (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017519A1 (en) 2013-07-30 2015-02-05 Phaserx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
EP3247328A1 (en) 2015-01-21 2017-11-29 PhaseRx, Inc. Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
ES2922760T3 (es) 2015-10-22 2022-09-20 Modernatx Inc Vacunas de virus respiratorios
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
SG11201810816QA (en) 2016-06-07 2018-12-28 Modernatx Inc Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto
EP3512944B1 (en) 2016-09-14 2022-07-06 ModernaTX, Inc. High purity rna compositions and methods for preparation thereof
EP3562510A4 (en) 2016-12-30 2021-01-06 Genevant Sciences GmbH BRANCHED PEG MOLECULES AND ASSOCIATED COMPOSITIONS AND PROCEDURES
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
EP4397757A3 (en) 2017-08-18 2024-10-23 ModernaTX, Inc. Rna polymerase variants
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
MA49914A (fr) 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
LT3703658T (lt) 2017-10-31 2022-07-25 Astrazeneca Ab Lipidų nanodalelės, skirtos modifikuotos rnr, koduojančios vegf-a polipeptidą, pristatymui
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
JP2022532075A (ja) * 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａを送達するために脂質ナノ粒子を使用する方法、及びこの脂質ナノ粒子を含む医薬組成物
CA3150061A1 (en) * 2019-08-07 2021-02-11 Modernatx, Inc. Compositions and methods for enhanced delivery of agents
WO2021155274A1 (en) * 2020-01-31 2021-08-05 Modernatx, Inc. Methods of preparing lipid nanoparticles
CN113185421B (zh) * 2020-11-27 2022-01-25 广州市锐博生物科技有限公司 脂质化合物及其组合物
CN114149337B (zh) * 2021-07-07 2022-04-29 天津键凯科技有限公司 一种用于核酸递送的新型可电离脂质及其lnp组合物
WO2023031394A1 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN113941011A (zh) * 2021-10-15 2022-01-18 浙江汇科泽华生物技术有限公司 一种含可离子化阳离子脂质的纳米脂质体颗粒及制备方法
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CN114957027B (zh) 2022-01-13 2023-05-19 北京悦康科创医药科技股份有限公司 一种阳离子脂质化合物、包含其的组合物及用途
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN114456081B (zh) * 2022-02-15 2025-03-11 浙江汇科泽华生物技术有限公司 一种可离子化脂质及其制备方法和应用
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CN119654141A (zh) * 2022-08-18 2025-03-18 苏州艾博生物科技有限公司 脂质纳米颗粒的组合物
CN115197431B (zh) * 2022-09-15 2022-11-29 清华大学 脂质偶联完全可降解水溶性聚合物的合成及应用
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
CN116474120A (zh) * 2023-04-03 2023-07-25 臻赫医药(杭州)有限公司 重编程因子抗衰老mRNA组合物、制备方法及应用
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025046121A1 (en) 2023-09-01 2025-03-06 Novoarc Gmbh Lipid nanoparticle with nucleic acid cargo and ionizable lipid

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
CA2743255C (en) 2008-12-03 2014-02-18 Andrew Pecora Infarct area perfusion-improving compositions and methods of vascular injury repair
EP2370581B1 (en) 2008-12-04 2016-08-03 CuRNA, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2012103985A2 (en) 2010-12-16 2012-08-09 Steve Pascolo Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
EP3460064B8 (en) 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Efficient protein expression in vivo using modified rna (mod-rna)
AU2012352180A1 (en) * 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
US10501513B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) * 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151672A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of oncology-related proteins and peptides
US9663564B2 (en) * 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015024667A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Method for increasing expression of rna-encoded proteins
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
US20180085474A1 (en) 2015-01-23 2018-03-29 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
SI3350157T1 (sl) * 2015-09-17 2022-04-29 Modernatx, Inc. Sestave za doziranje terapevtskih sredstev v celice
SG11201810816QA (en) * 2016-06-07 2018-12-28 Modernatx Inc Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
MX2016016339A (es) 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
LT3703658T (lt) 2017-10-31 2022-07-25 Astrazeneca Ab Lipidų nanodalelės, skirtos modifikuotos rnr, koduojančios vegf-a polipeptidą, pristatymui
CN114375190A (zh) 2019-05-08 2022-04-19 阿斯利康(瑞典)有限公司 用于皮肤和伤口的组合物及其使用方法

Also Published As

Publication number Publication date
US20200338004A1 (en) 2020-10-29
HRP20220843T1 (hr) 2022-10-14
JP2021508434A (ja) 2021-03-11
SG11202003941XA (en) 2020-05-28
JP2023138984A (ja) 2023-10-03
RS63389B1 (sr) 2022-08-31
WO2019089818A1 (en) 2019-05-09
CA3080592A1 (en) 2019-05-09
KR20200081420A (ko) 2020-07-07
JP7308000B2 (ja) 2023-07-13
HUE059049T2 (hu) 2022-10-28
BR112020008404A2 (pt) 2020-11-03
IL274230B2 (en) 2023-12-01
EA202090919A1 (ru) 2020-09-09
MA50522A (fr) 2021-05-26
PT3703658T (pt) 2022-07-18
MA50522B1 (fr) 2022-09-30
IL274230B1 (en) 2023-08-01
US11696892B2 (en) 2023-07-11
SI3703658T1 (sl) 2022-09-30
EP3703658B1 (en) 2022-05-04
SMT202200296T1 (it) 2022-09-14
ES2922462T3 (es) 2022-09-15
AU2018358049A1 (en) 2020-05-21
IL274230A (en) 2020-06-30
CN111356444A (zh) 2020-06-30
DK3703658T3 (da) 2022-07-18
PL3703658T3 (pl) 2022-08-22
EP3703658A1 (en) 2020-09-09
CY1125373T1 (el) 2024-09-20

Similar Documents

Publication Publication Date Title
IL274230A (en) Lipid nanoparticles for delivery of modified RNA encoding VEGF-A polypeptide
IL291932B2 (en) Nanoparticle preparations for prolonged treatment
IL252291A0 (en) A cationic lipid that undergoes ionization to provide RNA
SI3476575T1 (sl) 3D tiskalnik s svetlobnim utrjevanjem
HK1247831A1 (zh) 蛋白質或肽傳遞用的可溶性微針
HK1256138A1 (zh) 基於細菌的蛋白遞送
HK1251159A1 (zh) 改善的納米顆粒遞送系統
HK1248248A1 (zh) 廣譜抗感染肽
IL262310A (en) Advanced methods of gene insertion
IL258982A (en) Method for producing a recombinant protein
PT3285813T (pt) Administração do gene smad7 como um produto terapêutico
GB201417730D0 (en) Fuel delivery control
HK1255586A1 (zh) 含有多肽的醫藥組合物
HK1206556A2 (en) Information delivery method
GB201404028D0 (en) Anti-nausea composition for nasal inhalation comprising natural products